Replies to post #1732589 on BB's Stock Haven

[NightKilla]

CYCC Sapacitabine should be the first drug to hit the market. Currently in preparation for Phase III trials



This drug is believed to have a sales opportunity of over $2 billion annually!!

Exclusive rights in nearly all world territories for CYC682 were acquired from Sankyo by Cyclacel Limited in 2003!!

Sapacitabine received the orphan drug designation from the European Medicines Evaluation Agency (EMEA) for the indications of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in May 2008!!

The orphan drug designation provides for 10 years of market exclusivity in the European Union for sapacitabine, if (when) approved…